EGFR and non-small cell lung carcinoma: Currently, liquid biopsy is predominantly used in advanced-stage NSCLC to identify molecular targets at the initial clinical diagnosis and to detect resistance mutations after progression on targeted therapies, particularly those targeting EGFR [21].